Neuropsychiatric manifestations of SLE (NPSLE) is associated with increased morbidity
and mortality, intractable, complicating, and poor prognosis [
1
,
2
,
3
]. Although the severity of NPSLE correlates with poor prognosis, no established treatment
protocol and resistance to general treatment in many cases are making this condition
worse. Existing studies has shown expression of key B cell cytokines such as BAFF
and IL-6 were increased in SLE [
[4]
,
[5]
]. Belimumab, an anti-BAFF monoclonal antibody, was approved by the FDA for use in
treating SLE. Belimumab has recently been used for the treatment of a variety of SLE
disease conditions [
[4]
]. To date, reports on Belimumab treatment for SLE have covered various conditions,
resulting in a decrease in the SLE DAI score, arthropathy, nephropathy, thrombocytopenia
and hemolytic anemia, while the effect of Belimumab on refractory NPSLE is still unclear
[
[6]
,
[7]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives.Drugs. 2016; 76: 459-483
- Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations.Nat Rev Rheumatol. 2010; 6: 358-367
- Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients.Plos One. 2013; 8: e55843
- European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.Ann Rheum Dis. 2019; 78: 1151-1159
- Clinical predictors of response and discontinuation of Belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study.J Autoimmun. 2018; 86: 1-8
- Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms.Arthritis Res Ther. 2008; 10: R97
- Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus.Scand J Rheumatol. 2011; 40: 363-372
- Systemic Lupus Erythematosus (SLE) therapy: the old and the new.Rheumatol Ther. 2020; 7: 433-446
- Recent progress in neuropsychiatric systemic lupus erythematosus.Brain Nerve. 2013; 65 (Japanese. PMID: 24200603): 1255-1267
Article info
Publication history
Published online: July 02, 2021
Accepted:
June 7,
2021
Received:
June 2,
2021
Identification
Copyright
© 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
